ALKERMES | ALKS - Assets

Stock Price
31.91
Daily Change
-0.09 -0.28%
Monthly
-5.73%
Yearly
-9.65%
Q1 Forecast
30.94

ALKERMES reported $2.33B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Coherus Biosciences USD 516.52M 77.05M Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Heron Therapeutics USD 248.95M 16.86M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 28.09M 2.33M Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Otsuka Holdings JPY 4.2T 238.02B Dec/2025
Ovoca Bio EUR 11.41M 3.36M Jun/2022
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025